Trial · NCT00774306
Antiepileptic Drugs and Vascular Risk Markers
NCT00774306, Not applicable, Terminated, Thomas Jefferson University; results first posted 2014-11-25
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Antiepileptic Drugs and Vascular Risk Markers. Trials, record NCT00774306. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00774306
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Antiepileptic Drugs and Vascular Risk Markers
- NCT number
- NCT00774306
- Status
- Terminated
- Phases
- Not applicable
- Enrollment
- 52 participants, actual
- Lead sponsor
- Thomas Jefferson University
- Conditions
- Subarachnoid Hemorrhage
- Interventions
- phenytoin, valproate, levetiracetam
- First posted
- 2008-10-17
- Last updated
- 2017-12-18
- Results first posted
- 2014-11-25
- Limitations and caveats
Study terminated due to 1) change in clinical practice; 2) inadequate recruitment and follow-up.~Number of pts providing full data was \<15% of goal. Because of this, any analysis of data was considered futile, and no analyses were performed.
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Serum Cholesterol, Non-HDL Cholesterol, HDL Cholesterol, Lipoprotein(a), and C-reactive Protein From Baseline to Second Draw and Third Draw in Each of the 4 Study Arms | 8 weeks, 16 weeks | |
| Secondary | Incidence of Acute Seizures, Incidence of Late Seizures, Overall Neurologic Function (as Measured by Modified Rankin Scale Scores) | 8 weeks, 16 weeks |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in Serum Cholesterol, Non-HDL Cholesterol, HDL Cholesterol, Lipoprotein(a), and C-reactive Protein From Baseline to Second Draw and Third Draw in Each of the 4 Study Arms | 8 weeks, 16 weeks | |||
| SECONDARY | Incidence of Acute Seizures, Incidence of Late Seizures, Overall Neurologic Function (as Measured by Modified Rankin Scale Scores) | 8 weeks, 16 weeks |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow12
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Phenytoin | 24 | |
| Overall Study | STARTED | Valproate | 5 | |
| Overall Study | STARTED | Levetiracetam | 16 | |
| Overall Study | STARTED | No Anticonvulsant | 7 | |
| Overall Study | COMPLETED | Phenytoin | 6 | |
| Overall Study | COMPLETED | Valproate | 3 | |
| Overall Study | COMPLETED | Levetiracetam | 8 | |
| Overall Study | COMPLETED | No Anticonvulsant | 2 | |
| Overall Study | NOT COMPLETED | Phenytoin | 18 | |
| Overall Study | NOT COMPLETED | Valproate | 2 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 participant flowAdverse events28
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | urinary tract infection | Infections and infestations | Phenytoin | 0 | 24 | |
| other | urinary tract infection | Infections and infestations | Valproate | 1 | 5 | |
| other | urinary tract infection | Infections and infestations | Levetiracetam | 0 | 16 | |
| other | urinary tract infection | Infections and infestations | No Anticonvulsant | 0 | 7 | |
| serious | vasospasm | Nervous system disorders | Phenytoin | 1 | 24 | |
| serious | vasospasm | Nervous system disorders | Valproate | 1 | 5 | |
| serious | vasospasm | Nervous system disorders | Levetiracetam | 2 | 16 | |
| serious | vasospasm | Nervous system disorders | No Anticonvulsant | 1 | 7 | |
| serious | deep venous thrombosis | Vascular disorders | Phenytoin | 1 | 24 | |
| serious | deep venous thrombosis | Vascular disorders | Valproate | 0 | 5 |
1 to 10 of 28Source ClinicalTrials.gov
See all 28 adverse eventsAdverse event totals12
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Phenytoin | ||
| Total, all-cause mortality | Valproate | ||
| Total, all-cause mortality | Levetiracetam | ||
| Total, all-cause mortality | No Anticonvulsant | ||
| Total, other adverse events | Phenytoin | 0 | 24 |
| Total, other adverse events | Valproate | 1 | 5 |
| Total, other adverse events | Levetiracetam | 0 | 16 |
| Total, other adverse events | No Anticonvulsant | 0 | 7 |
| Total, serious adverse events | Phenytoin | 4 | 24 |
| Total, serious adverse events | Valproate | 1 | 5 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 adverse event totalsPapers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| K23NS058669 | The Effects of Antiepileptic Drugs on Serologic Indices of Vascular Risk | MINTZER, SCOTT | THOMAS JEFFERSON UNIVERSITY | NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE | 2008 to 2012 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00774306
GET https://conductscience.org/api/trials/v1/NCT00774306/events?page=2